Base de dados : MEDLINE
Pesquisa : C19 [Categoria DeCS]
Referências encontradas : 7662 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 767 ir para página                         

  1 / 7662 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29431323
[Au] Autor:Tarmaeva IY; Efimova NV; Baglushkina SY
[Ti] Título:[Hygienic estimation of the nutrition and the risk of morbidity associated with its violation].
[So] Source:Gig Sanit;95(9):868-72, 2016.
[Is] ISSN:0016-9900
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Among risk factors possessing a main importance in the shaping of theA public health the leading place is featured to the rational nutrition. Presented results testify to the absence of stable group in the adult population of Irkutsk who eats regularly, with a rational multiplicity and having all essential meal reception and the recommended food package. There was revealed the role of nutrition in shaping of morbidity rate in the adult population. The risk of circulatory diseases was established to account of 2.5 (95% CI 2.1-3.6), the infectious and parasitic diseases - 2.4 (95% CI 1.7-3.5), the endocrine system - 2,2 (95% CI 1.4-3.4), and urinary system - 2.3 (95% CI 1.7 to 3.0).
[Mh] Termos MeSH primário: Deficiências Nutricionais/epidemiologia
Comportamento Alimentar
Estado Nutricional
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Doenças Cardiovasculares/epidemiologia
Doenças Transmissíveis/epidemiologia
Doenças do Sistema Endócrino/epidemiologia
Feminino
Seres Humanos
Lactente
Masculino
Necessidades Nutricionais
Medição de Risco
Fatores de Risco
Sibéria/epidemiologia
Doenças Urológicas/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180213
[St] Status:MEDLINE


  2 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29190135
[Au] Autor:Fonseca VA; Bloomgarden ZT; Dagogo-Jack S; Grunberger G; Einhorn D; Garber AJ; Handelsman Y; Hirsch IB; Umpierrez GE
[Ti] Título:AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.
[So] Source:Endocr Pract;23(11):1345-1349, 2017 Nov.
[Is] ISSN:1530-891X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. ABBREVIATIONS: BPCIA = Biologics Price Competition and Innovation Act; FDA = Food and Drug Administration; FFDC = Federal Food Drug and Cosmetics Act; PHS = Public Health Services Act; TE = therapeutic equivalence.
[Mh] Termos MeSH primário: Produtos Biológicos/uso terapêutico
Medicamentos Biossimilares/uso terapêutico
Doenças do Sistema Endócrino/tratamento farmacológico
[Mh] Termos MeSH secundário: Endocrinologia
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biological Products); 0 (Biosimilar Pharmaceuticals)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.4158/EP-2017-0052


  3 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29309627
[Au] Autor:Kharade SS; Parekh VI; Agarwal SK
[Ad] Endereço:Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
[Ti] Título:Functional Defects From Endocrine Disease-Associated Mutations in HLXB9 and Its Interacting Partner, NONO.
[So] Source:Endocrinology;159(2):1199-1212, 2018 02 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The insulin-secreting pancreatic neuroendocrine tumors, insulinomas, characterized by increased pancreatic islet ß-cell proliferation, express the phosphorylated isoform of the ß-cell differentiation factor HLXB9 that interacts with NONO/p54NRB, a survival factor. Interestingly, two different homozygous germline mutations in HLXB9, p.F248L and p.F272L, were reported in neonatal diabetes, a condition with functional ß-cell deficiency. Also, two somatic heterozygous NONO mutations were found in endocrine-related tumors, p.H146R (parathyroid) and p.R293H (small intestine neuroendocrine tumor). However, the biological consequence of the mutations, and the role of HLXB9-NONO interaction in normal or abnormal ß cells, is not known. Expression, localization, and functional analysis of the clinically relevant HLXB9 and NONO mutants showed that HLXB9/p.F248L mutant localized in the nucleus but lacked phosphorylation, and NONO/p.R293H mutant was structurally impaired. The HLXB9 and NONO mutants retained the ability to interact, and overexpression of wild-type or mutant HXLB9 in MIN6 cells suppressed cell proliferation. To further understand the biological consequence of the HLXB9-NONO interaction, we mapped the NONO-interacting region in HLXB9. An 80-amino acid conserved region of HLXB9 could compete with full-length HLXB9 to interact with NONO; however, in functional assays, nuclear expression of this HLXB9-conserved region in MIN6 cells did not interfere with cell proliferation. Overall, our results highlight the importance of HLXB9 in conditions of ß-cell excess (insulinomas) and in conditions of ß-cell loss or dysfunction (diabetes). Our studies implicate therapeutic strategies for either reducing ß-cell proliferation in insulinomas or alleviating normal ß-cell deficiency in diabetes through the modulation of HLXB9 phosphorylation.
[Mh] Termos MeSH primário: Doenças do Sistema Endócrino/genética
Proteínas de Homeodomínio/genética
Proteínas de Homeodomínio/metabolismo
Proteínas Associadas à Matriz Nuclear/genética
Proteínas Associadas à Matriz Nuclear/metabolismo
Fatores de Transcrição de Octâmero/genética
Fatores de Transcrição de Octâmero/metabolismo
Proteínas de Ligação a RNA/genética
Proteínas de Ligação a RNA/metabolismo
Fatores de Transcrição/genética
Fatores de Transcrição/metabolismo
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Diabetes Mellitus/genética
Doenças do Sistema Endócrino/metabolismo
Mutação em Linhagem Germinativa
Seres Humanos
Recém-Nascido
Células Secretoras de Insulina/metabolismo
Células Secretoras de Insulina/patologia
Camundongos
Camundongos Transgênicos
Mutação
Ligação Proteica
Proteínas Proto-Oncogênicas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., INTRAMURAL
[Nm] Nome de substância:
0 (Homeodomain Proteins); 0 (MNX1 protein, human); 0 (Men1 protein, mouse); 0 (NONO protein, human); 0 (Nuclear Matrix-Associated Proteins); 0 (Octamer Transcription Factors); 0 (Proto-Oncogene Proteins); 0 (RNA-Binding Proteins); 0 (Transcription Factors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180109
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-03155


  4 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187509
[Au] Autor:Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
[Ad] Endereço:Department of EndocrinologyRoyal North Shore Hospital, Sydney, Australia.
[Ti] Título:The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
[So] Source:Eur J Endocrinol;178(2):175-182, 2018 Feb.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Endocrine immune-related adverse events (endocrinopathies) are increasingly prevalent with the use of immune checkpoint inhibitors for the treatment of metastatic melanoma and other malignancies. There are no evidence-based guidelines for the screening or management of such patients. To describe the spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors. DESIGN: A prospective study conducted at Melanoma Institute Australia between April 2014 and October 2015. METHODS: A total of 177 patients were treated with (a) ipilimumab ( = 15), (b) anti-PD-1 (nivolumab, pembrolizumab) ( = 103) or (c) combination ipilimumab and anti-PD-1 ( = 59) and were screened and managed for the subsequent endocrinopathies. The main outcome measures were the incidence and kinetics of endocrinopathy by immunotherapy drug class. RESULTS: Thirty-one patients (18%) developed an endocrine immune-related adverse event (thyroid dysfunction: 14%, hypophysitis: 6% and autoimmune diabetes: 0.6%). Combination immunotherapy was more likely to result in a single or multiple endocrinopathy compared to anti-PD-1 monotherapy (27% vs 9% and 7% vs 0% respectively, < 0.01). Endocrinopathies occurred after a median of 8 weeks from treatment commencement (range: 12-225 days), with combination immunotherapy resulting in significantly earlier onset compared to ipilimumab (median: 30 vs 76 days, = 0.046). The majority of endocrinopathies were identified in asymptomatic patients with hormonal screening. There were no baseline predictors for endocrinopathy. CONCLUSIONS: Combination immunotherapy has a greater risk of development of endocrinopathy compared to anti-PD-1 monotherapy. Regular biochemical profiling of patients, particularly within the first twelve weeks, results in early detection of endocrinopathy to minimise morbidity.
[Mh] Termos MeSH primário: Doenças do Sistema Endócrino/epidemiologia
Doenças do Sistema Endócrino/etiologia
Imunoterapia/efeitos adversos
Melanoma/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anticorpos Monoclonais/efeitos adversos
Anticorpos Monoclonais/uso terapêutico
Anticorpos Monoclonais Humanizados/efeitos adversos
Austrália
Doenças Autoimunes/etiologia
Diabetes Mellitus/epidemiologia
Diabetes Mellitus/etiologia
Diabetes Mellitus/imunologia
Quimioterapia Combinada/efeitos adversos
Doenças do Sistema Endócrino/fisiopatologia
Feminino
Seres Humanos
Hipofisite/epidemiologia
Hipofisite/etiologia
Ipilimumab/efeitos adversos
Masculino
Meia-Idade
Receptor de Morte Celular Programada 1/imunologia
Estudos Prospectivos
Doenças da Glândula Tireoide/epidemiologia
Doenças da Glândula Tireoide/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Ipilimumab); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 31YO63LBSN (nivolumab); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180110
[Lr] Data última revisão:
180110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0810


  5 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29192748
[Au] Autor:Hernán Martínez J; Mangual Garcia MM; Gutiérrez Acevedo M; Sánchez Cruz A; Laboy I; Rivera C; Mansilla P; Palermo Garofalo C; Lourdes Miranda M; Torres Rafael O
[Ti] Título:A middle aged woman with isolated ACTH deficiency associated with transient growth hormone deficiency.
[So] Source:Bol Asoc Med P R;108(1):3-6, 2016.
[Is] ISSN:0004-4849
[Cp] País de publicação:Puerto Rico
[La] Idioma:eng
[Ab] Resumo:Isolated ACTH deficiency (IAD) is a rare entity characterized by secondary adrenal insufficiency with low levels of serum cortisol, decreased production of ACTH, adequate secretion of other pituitary hormones and normal pituitary structure on radioimaging. The prevalence of IAD as a cause of secondary adrenal insufficiency has not been determined. Impairment of growth hormone (GH) secretion has been noted in 20 to 30% of patients with IAD which is normalized after glucocorticoid replacement. We report the case of a 50 years-old female with symptoms and laboratory results suggestive of adrenal insufficiency. Insulin tolerance test confirmed ACTH and growth hormone deficiency. The rest of the anterior pituitary hormones were normal. A pituitary MRI was unremarkable. Glucocorticoid replacement therapy started and eight months afterwards glucagon stimulation test revealed persistent ACTH deficiency but nor- mal growth hormone secretion. IAD can present with nonspecific symptoms and could be potentially fatal in an acute stressful period. Prompt recognition is essential to decrease morbidity and mortality.
[Mh] Termos MeSH primário: Hormônio Adrenocorticotrópico/deficiência
Doenças do Sistema Endócrino/complicações
Doenças Genéticas Inatas/complicações
Glucocorticoides/administração & dosagem
Hormônio do Crescimento Humano/deficiência
Hipoglicemia/complicações
Resistência à Insulina
[Mh] Termos MeSH secundário: Doenças do Sistema Endócrino/diagnóstico
Feminino
Doenças Genéticas Inatas/diagnóstico
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hipoglicemia/diagnóstico
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Glucocorticoids); 12629-01-5 (Human Growth Hormone); 9002-60-2 (Adrenocorticotropic Hormone)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171214
[Lr] Data última revisão:
171214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  6 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29046326
[Au] Autor:Eastell R; Pigott T; Gossiel F; Naylor KE; Walsh JS; Peel NFA
[Ad] Endereço:Academic Unit of Bone MetabolismUniversity of Sheffield, Sheffield, UK r.eastell@sheffield.ac.uk.
[Ti] Título:DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?
[So] Source:Eur J Endocrinol;178(1):R19-R31, 2018 Jan.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bone turnover markers (BTMs) are useful in clinical practice as they are inexpensive, and they have proven useful for treatment monitoring and identification of poor adherence. BTMs cannot be used in individual patients for identifying accelerated bone loss or an increase in fracture risk or in deciding on the optimal therapy. They are useful for monitoring both anti-resorptive and anabolic treatment. Response can be defined as a result that exceeds an absolute target, or by a change greater than the least significant change; if such a response is not present, then poor compliance or secondary osteoporosis are likely causes. A baseline BTM measurement is not always made; in that case, a value of BTM on anti-resorptive treatment that is low or low normal or above the reference interval for anabolic therapy may be taken to indicate a satisfactory response. We provide an approach to using these bone turnover markers in clinical practice by describing algorithms for anti-resorptive and anabolic therapy and describing the changes we observe in the clinical practice setting.
[Mh] Termos MeSH primário: Remodelação Óssea/fisiologia
Doenças do Sistema Endócrino/diagnóstico
Doenças do Sistema Endócrino/metabolismo
[Mh] Termos MeSH secundário: Biomarcadores/metabolismo
Densidade Óssea/fisiologia
Reabsorção Óssea/diagnóstico
Reabsorção Óssea/metabolismo
Seres Humanos
Osteocalcina/metabolismo
Fragmentos de Peptídeos/metabolismo
Pró-Colágeno/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Peptide Fragments); 0 (Procollagen); 0 (procollagen Type I N-terminal peptide); 104982-03-8 (Osteocalcin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171020
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0585


  7 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29095280
[Au] Autor:Zeng MF; Chen L; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
[Ad] Endereço:aDepartment of Endocrinology, Huashan Hospital North bDepartment of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.
[Ti] Título:Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
[So] Source:Medicine (Baltimore);96(44):e8426, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Nivolumab is a monoclonal IgG antibody blocking programmed death receptor-1 (PD1), leading to restoration of the natural T-cell-mediated immune response against the cancer cells. However, it also causes plenty of autoimmune-related adverse events, which often involves endocrine system. PATIENT CONCERNS: A 54-year-old male with renal clear cell carcinoma was treated with nivolumab intravenously. Routine monitoring showed elevated thyroid-stimulating hormone and low free thyroxine after the 6th administration of nivolumab. After the 12th administration, he developed general fatigue, recurrent hypoglycemia, and relative hypotension. Laboratory tests showed low sodium, low morning cortisol without correspondence increase of corticotrophin (ACTH). Other pituitary hormones were normal. MRI showed no space-occupying lesions, but heterogeneous enhancement of the pituitary gland. DIAGNOSES: Primary hypothyroidism and isolated ACTH deficiency. The etiologies were assumed to be nivolumab induced autoimmune lymphocytic thyroiditis and hypophysitis, respectively. INTERVENTIONS: Hormone replacements with levothyroxine and acetate cortisone were given orally. Nivolumab was adjusted to lower dose and longer interval. OUTCOMES: The patient felt good after adequate replacement. Nivolumab was returned to routine dose and interval six months later. And the metastasis was not obviously progressed during this time. LESSONS: The present report provides the first detailed presentation of combined hypothyroidism and isolated ACTH deficiency induced by nivolumab. Adrenal deficiency often develops insidiously. We suggest routine monitoring of fasting blood-glucose, blood pressure and serum sodium as well as thyroid function during nivolumab and other cancer immunotherapies. When unexpected fatigue, hypoglycemia, hypotension or hyponatremia appeared, adrenal deficiency should be taken into consideration.
[Mh] Termos MeSH primário: Hormônio Adrenocorticotrópico/deficiência
Anticorpos Monoclonais/efeitos adversos
Antineoplásicos/efeitos adversos
Carcinoma de Células Renais/tratamento farmacológico
Doenças do Sistema Endócrino/induzido quimicamente
Doenças Genéticas Inatas/induzido quimicamente
Hipoglicemia/induzido quimicamente
Hipotireoidismo/induzido quimicamente
Neoplasias Renais/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 31YO63LBSN (nivolumab); 9002-60-2 (Adrenocorticotropic Hormone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171103
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008426


  8 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28982960
[Au] Autor:Huguet I; Grossman A
[Ad] Endereço:Department of EndocrinologyHospital de la Princesa, Madrid, Spain ihm.huguet@gmail.com.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Flushing: current concepts.
[So] Source:Eur J Endocrinol;177(5):R219-R229, 2017 Nov.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Flushing can be defined as a sensation of warmth accompanied by erythema that most commonly is seen on the face and which occurs in episodic attacks. Such a problem can be clinically problematic, since many conditions and drugs can be related to flushing, and while often there appears to be no underlying organic disease, it is important to exclude disorders since they may be life-threatening conditions. DESIGN AND METHODS: We performed a search in MEDLINE using the terms 'flushing' in combination with 'carcinoid syndrome', 'pheochromocytoma', 'mastocytosis', 'menopausal hot flush' and 'treatment'. European and American guidelines relating to neuroendocrine tumours, mastocytosis and menopause were reviewed. RESULTS: In this review, we discuss the main causes of flushing and propose an algorithm based on pathogenesis, which can be used to guide the clinical evaluation process. We also review recent significant developments in the assessment and treatment of the carcinoid syndrome and menopausal hot flushes, which should guide the clinical practice regarding this common but sometimes confusing condition. CONCLUSIONS: When evaluating flushing, a precise systematic approach is needed to exclude potentially serious underlying causes, although despite this, the cause of the disorder is not always found. If symptoms are not progressive, the patient should be advised about its apparently benign nature in order to avoid unnecessary studies or initiating treatments of minimal benefit.
[Mh] Termos MeSH primário: Gerenciamento Clínico
Doenças do Sistema Endócrino/diagnóstico
Doenças do Sistema Endócrino/terapia
Rubor/diagnóstico
Rubor/terapia
[Mh] Termos MeSH secundário: Neoplasias das Glândulas Suprarrenais/diagnóstico
Neoplasias das Glândulas Suprarrenais/epidemiologia
Neoplasias das Glândulas Suprarrenais/terapia
Algoritmos
Doenças do Sistema Endócrino/epidemiologia
Rubor/epidemiologia
Fogachos/diagnóstico
Fogachos/epidemiologia
Fogachos/terapia
Seres Humanos
Síndrome do Carcinoide Maligno/diagnóstico
Síndrome do Carcinoide Maligno/epidemiologia
Síndrome do Carcinoide Maligno/terapia
Menopausa/fisiologia
Tumores Neuroendócrinos/diagnóstico
Tumores Neuroendócrinos/epidemiologia
Tumores Neuroendócrinos/terapia
Feocromocitoma/diagnóstico
Feocromocitoma/epidemiologia
Feocromocitoma/terapia
Sudorese/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0295


  9 / 7662 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28822238
[Au] Autor:Zota AR; Shamasunder B
[Ad] Endereço:Department of Environmental and Occupational Health, George Washington University Milken Institute School of Public Health, Washington DC. Electronic address: azota@gwu.edu.
[Ti] Título:The environmental injustice of beauty: framing chemical exposures from beauty products as a health disparities concern.
[So] Source:Am J Obstet Gynecol;217(4):418.e1-418.e6, 2017 Oct.
[Is] ISSN:1097-6868
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The obstetrics-gynecology community has issued a call to action to prevent toxic environmental chemical exposures and their threats to healthy human reproduction. Recent committee opinions recognize that vulnerable and underserved women may be impacted disproportionately by environmental chemical exposures and recommend that reproductive health professionals champion policies that secure environmental justice. Beauty product use is an understudied source of environmental chemical exposures. Beauty products can include reproductive and developmental toxicants such as phthalates and heavy metals; however, disclosure requirements are limited and inconsistent. Compared with white women, women of color have higher levels of beauty product-related environmental chemicals in their bodies, independent of socioeconomic status. Even small exposures to toxic chemicals during critical periods of development (such as pregnancy) can trigger adverse health consequences (such as impacts on fertility and pregnancy, neurodevelopment, and cancer). In this commentary, we seek to highlight the connections between environmental justice and beauty product-related chemical exposures. We describe racial/ethnic differences in beauty product use (such as skin lighteners, hair straighteners, and feminine hygiene products) and the potential chemical exposures and health risks that are associated with these products. We also discuss how targeted advertising can take advantage of mainstream beauty norms to influence the use of these products. Reproductive health professionals can use this information to advance environmental justice by being prepared to counsel patients who have questions about toxic environmental exposures from beauty care products and other sources. Researchers and healthcare providers can also promote health-protective policies such as improved ingredient testing and disclosure for the beauty product industry. Future clinical and public health research should consider beauty product use as a factor that may shape health inequities in women's reproductive health across the life course.
[Mh] Termos MeSH primário: Cosméticos/efeitos adversos
[Mh] Termos MeSH secundário: Carcinógenos/toxicidade
Doenças do Sistema Endócrino/induzido quimicamente
Feminino
Disparidades nos Níveis de Saúde
Seres Humanos
Gravidez
Resultado da Gravidez
Teratogênios/toxicidade
Saúde da Mulher
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carcinogens); 0 (Cosmetics); 0 (Teratogens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170820
[St] Status:MEDLINE


  10 / 7662 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28689073
[Au] Autor:Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
[Ad] Endereço:Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. Electronic address: mario.sznol@yale.edu.
[Ti] Título:Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
[So] Source:Cancer Treat Rev;58:70-76, 2017 Jul.
[Is] ISSN:1532-1967
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Agents that modulate immune checkpoint proteins, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death receptor-1 (PD-1), have become a mainstay in cancer treatment. The clinical benefit afforded by immune checkpoint inhibitors can be accompanied by immune-related adverse events (irAE) that affect the skin, gastrointestinal tract, liver, and endocrine system. The types of irAEs associated with immune checkpoint inhibitors are generally consistent across tumor types. Immune-related endocrine events can affect the pituitary, thyroid, and adrenal glands, as well as other downstream target organs. These events are unique when compared with other irAEs because the manifestations are often irreversible. Immune-related endocrine events are typically grade 1/2 in severity and often present with non-specific symptoms, making them difficult to diagnose. The mechanisms underlying immune-related target organ damage in select individuals remain mostly undefined. Management includes close patient monitoring, appropriate laboratory testing for endocrine function, replacement of hormones, and consultation with an endocrinologist when appropriate. An awareness of the symptoms and management of immune-related endocrine events may aid in the safe and appropriate use of immune checkpoint inhibitors in clinical practice.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Doenças do Sistema Endócrino/induzido quimicamente
Doenças do Sistema Endócrino/terapia
Neoplasias/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/efeitos adversos
Anticorpos Monoclonais Humanizados/efeitos adversos
Antígeno B7-H1/antagonistas & inibidores
Antígeno CTLA-4/antagonistas & inibidores
Doenças do Sistema Endócrino/diagnóstico
Seres Humanos
Ipilimumab
Receptor de Morte Celular Programada 1/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (B7-H1 Antigen); 0 (CD274 protein, human); 0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (Ipilimumab); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 0 (avelumab); 0 (durvalumab); 31YO63LBSN (nivolumab); 52CMI0WC3Y (atezolizumab); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170710
[St] Status:MEDLINE



página 1 de 767 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde